Hologic, Inc. to Post Q1 2019 Earnings of $0.58 Per Share, Piper Jaffray Companies Forecasts (HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at Piper Jaffray Companies lifted their Q1 2019 earnings per share (EPS) estimates for Hologic in a research note issued on Monday, January 7th. Piper Jaffray Companies analyst W. Quirk now expects that the medical equipment provider will post earnings of $0.58 per share for the quarter, up from their previous forecast of $0.57. Piper Jaffray Companies has a “Overweight” rating and a $45.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Hologic’s FY2019 earnings at $2.40 EPS.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 EPS for the quarter, missing the Zacks’ consensus estimate of $0.59 by ($0.01). Hologic had a positive return on equity of 23.52% and a negative net margin of 3.46%. The company had revenue of $813.50 million during the quarter, compared to analysts’ expectations of $808.63 million. During the same period in the prior year, the firm earned $0.50 EPS. Hologic’s quarterly revenue was up 1.3% on a year-over-year basis.



Other equities analysts have also recently issued research reports about the stock. BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Hologic in a research note on Thursday, September 27th. Morgan Stanley cut their price objective on shares of Hologic from $47.00 to $44.00 and set an “equal weight” rating for the company in a research note on Thursday, October 11th. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a research note on Tuesday, November 13th. Finally, Canaccord Genuity reaffirmed a “hold” rating and issued a $43.00 price objective on shares of Hologic in a research note on Thursday, November 8th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Hologic presently has an average rating of “Hold” and a consensus target price of $43.33.

HOLX stock opened at $42.89 on Thursday. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.95. Hologic has a one year low of $35.10 and a one year high of $45.17. The company has a market capitalization of $12.17 billion, a price-to-earnings ratio of 19.23, a P/E/G ratio of 1.94 and a beta of 0.73.

A number of large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its holdings in Hologic by 20.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 112,968 shares of the medical equipment provider’s stock worth $4,484,000 after purchasing an additional 19,224 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec raised its holdings in Hologic by 3.6% in the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 62,600 shares of the medical equipment provider’s stock worth $2,488,000 after purchasing an additional 2,200 shares in the last quarter. Oregon Public Employees Retirement Fund bought a new position in Hologic in the 2nd quarter worth $1,197,000. BB&T Securities LLC raised its holdings in Hologic by 11.9% in the 2nd quarter. BB&T Securities LLC now owns 153,314 shares of the medical equipment provider’s stock worth $6,094,000 after purchasing an additional 16,329 shares in the last quarter. Finally, Raymond James & Associates raised its holdings in Hologic by 13.7% in the 2nd quarter. Raymond James & Associates now owns 101,016 shares of the medical equipment provider’s stock worth $4,015,000 after purchasing an additional 12,191 shares in the last quarter. Institutional investors own 91.77% of the company’s stock.

In related news, insider Peter J. Valenti III sold 4,740 shares of the company’s stock in a transaction on Friday, December 7th. The shares were sold at an average price of $42.20, for a total transaction of $200,028.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Christiana Stamoulis sold 13,257 shares of the company’s stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $44.50, for a total transaction of $589,936.50. Following the sale, the director now owns 48,296 shares of the company’s stock, valued at $2,149,172. The disclosure for this sale can be found here. Insiders have sold a total of 36,355 shares of company stock valued at $1,584,655 over the last quarter. 0.88% of the stock is currently owned by company insiders.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: What is Compound Interest?

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply